-
Je něco špatně v tomto záznamu ?
Synthetic Stimulator of Interferon Genes (STING) Agonists Induce a Cytokine-Mediated Anti-Hepatitis B Virus Response in Nonparenchymal Liver Cells
M. Pimkova Polidarova, L. Vanekova, P. Brehova, M. Dejmek, Z. Vavrina, G. Birkus, A. Brazdova
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Odkazy
PubMed
36472628
DOI
10.1021/acsinfecdis.2c00424
Knihovny.cz E-zdroje
- MeSH
- cytokiny metabolismus MeSH
- hepatitida B * farmakoterapie MeSH
- hepatocyty MeSH
- herpesvirus B * MeSH
- interferony metabolismus MeSH
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Chronic hepatitis B (CHB) remains a major public health problem worldwide, with limited treatment options, but inducing an antiviral response by innate immunity activation may provide a therapeutic alternative. We assessed the cytokine-mediated anti-hepatitis B virus (HBV) potential for stimulating the cyclic GMP-AMP synthase-stimulator of interferon genes (STING) pathway using STING agonists in primary human hepatocytes (PHH) and nonparenchymal liver cells (NPCs). The natural STING agonist, 2',3'-cyclic GMP-AMP, the synthetic analogue 3',3'-c-di(2'F,2'dAMP), and its bis(pivaloyloxymethyl) prodrug had strong indirect cytokine-mediated anti-HBV effects in PHH regardless of HBV genotype. Furthermore, STING agonists induced anti-HBV cytokine secretion in vitro, in both human and mouse NPCs, and triggered hepatic T cell activation. Cytokine secretion and lymphocyte activation were equally stimulated in NPCs isolated from control and HBV-persistent mice. Therefore, STING agonists modulate immune activation regardless of HBV persistence, paving the way toward a CHB therapy.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004609
- 003
- CZ-PrNML
- 005
- 20230509145428.0
- 007
- ta
- 008
- 230418s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acsinfecdis.2c00424 $2 doi
- 035 __
- $a (PubMed)36472628
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Pimkova Polidarova, Marketa $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo namesti 2, Prague 16000, Czech Republic $1 https://orcid.org/0000000331161328
- 245 10
- $a Synthetic Stimulator of Interferon Genes (STING) Agonists Induce a Cytokine-Mediated Anti-Hepatitis B Virus Response in Nonparenchymal Liver Cells / $c M. Pimkova Polidarova, L. Vanekova, P. Brehova, M. Dejmek, Z. Vavrina, G. Birkus, A. Brazdova
- 520 9_
- $a Chronic hepatitis B (CHB) remains a major public health problem worldwide, with limited treatment options, but inducing an antiviral response by innate immunity activation may provide a therapeutic alternative. We assessed the cytokine-mediated anti-hepatitis B virus (HBV) potential for stimulating the cyclic GMP-AMP synthase-stimulator of interferon genes (STING) pathway using STING agonists in primary human hepatocytes (PHH) and nonparenchymal liver cells (NPCs). The natural STING agonist, 2',3'-cyclic GMP-AMP, the synthetic analogue 3',3'-c-di(2'F,2'dAMP), and its bis(pivaloyloxymethyl) prodrug had strong indirect cytokine-mediated anti-HBV effects in PHH regardless of HBV genotype. Furthermore, STING agonists induced anti-HBV cytokine secretion in vitro, in both human and mouse NPCs, and triggered hepatic T cell activation. Cytokine secretion and lymphocyte activation were equally stimulated in NPCs isolated from control and HBV-persistent mice. Therefore, STING agonists modulate immune activation regardless of HBV persistence, paving the way toward a CHB therapy.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a cytokiny $x metabolismus $7 D016207
- 650 12
- $a herpesvirus B $7 D006568
- 650 _2
- $a hepatocyty $7 D022781
- 650 12
- $a hepatitida B $x farmakoterapie $7 D006509
- 650 _2
- $a interferony $x metabolismus $7 D007372
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vanekova, Lenka $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo namesti 2, Prague 16000, Czech Republic $u Faculty of Science, Charles University, Albertov 6, Prague 12800, Czech Republic $1 https://orcid.org/0000000225721336
- 700 1_
- $a Brehova, Petra $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo namesti 2, Prague 16000, Czech Republic $1 https://orcid.org/000000015353889X
- 700 1_
- $a Dejmek, Milan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo namesti 2, Prague 16000, Czech Republic $1 https://orcid.org/000000028195971X
- 700 1_
- $a Vavrina, Zdenek $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo namesti 2, Prague 16000, Czech Republic $u Faculty of Science, Charles University, Albertov 6, Prague 12800, Czech Republic $1 https://orcid.org/0000000260228918
- 700 1_
- $a Birkuš, Gabriel, $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo namesti 2, Prague 16000, Czech Republic $1 https://orcid.org/0000000298502150 $d 1972- $7 xx0301324
- 700 1_
- $a Brázdová, Andrea $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo namesti 2, Prague 16000, Czech Republic $1 https://orcid.org/0000000223846012 $7 ntk2015859863
- 773 0_
- $w MED00205751 $t ACS infectious diseases $x 2373-8227 $g Roč. 9, č. 1 (2023), s. 23-32
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36472628 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230509145425 $b ABA008
- 999 __
- $a ok $b bmc $g 1924980 $s 1190818
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 9 $c 1 $d 23-32 $e 20221206 $i 2373-8227 $m ACS infectious diseases $n ACS infect. dis. $x MED00205751
- LZP __
- $a Pubmed-20230418